DGAP-Adhoc: IPSEN to acquire all shares in Octreopharm Sciences GmbH

Eckert & Ziegler Strahlen- und Medizintechnik AG  / Key word(s):
Disposal/Strategic Company Decision 

19.05.2015 17:57

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Berlin, 19 May 2015. Eckert & Ziegler Radiopharma GmbH (EZR) and a group of
start-up investors have signed a purchase agreement with French
pharmaceutical company IPSEN for all shares of Octreopharm Science GmbH
(OPS), a drug development company located in Berlin-Buch. The deal, which
is subject to various conditions precedent, has an overall value of about
50 mm EUR, milestones included.

EZR owns about third of OPS and would book extraordinary profits from the
sale of shares if the deal becomes effective. Guidance about the profit
impact of the transaction will be given, once the deal is closed, in EZAG's
subsequent quarterly report at the latest.


---------------------------------------------------------------------------

Information and Explaination of the Issuer to this News:

'Helping OPS getting off the ground and positioning EZR as a service
partner for the radio-labeling of pharmaceuticals were our main objectives
when we started OPS five years ago in Berlin-Buch', said Dr. André Heß,
head of Eckert & Ziegler's pharmaceutical segment. 'We are happy now to
pass OPS on to a partner with an extensive expertise in neuroendocrine
tumors (NET). Furthermore, the deal includes a long term strategic
agreement between the purchaser and EZR, giving EZR a prominent role as a
contract manufacturer for the radio-labeling of the OPS therapeutic
compound.

OPS, who develops innovative medication for the clinical management of
neuroendocrine tumors, recently had convincing preliminary clinical results
for its lead compound OPS202. The company was founded in 2009 by nuclear
medicine industry insiders. OPS closed its first financing round in 2011,
with Eckert Life Science Accelerator, Berlin acting as lead investor for
KfW Mittelstandsbank together with VC Fonds Technologie Berlin (IBB
Beteiligungsgesellschaft). In a second round, OPS was supported by Shaanxi
Xinyida Investment Co. Ltd., China and Eckert & Ziegler AG.

If you have any questions, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de 

19.05.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Eckert & Ziegler Strahlen- und Medizintechnik AG
              Robert-Rössle-Str.10
              13125 Berlin
              Germany
Phone:        49 30 941084-138
Fax:          49 30 941084-112
E-mail:       karolin.riehle@ezag.de
Internet:     www.ezag.de
ISIN:         DE0005659700
WKN:          565970
Listed:       Regulated Market in Frankfurt (Prime Standard), Stuttgart;
              Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg,
              Munich
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------